ストックスクリーナーアプリを入手
7.38
2.22%
0.16
アフターアワーズ：
7.48
0.10
+1.36%
前日終値:
$7.22
開ける：
$7.17
24時間の取引高:
9.57M
Relative Volume:
1.64
時価総額：
$2.25B
収益：
$32.77M
当期純損益:
$-440.22M
株価収益率:
-3.2946
EPS:
-2.24
ネットキャッシュフロー:
$-400.48M
1週間 パフォーマンス:
-5.75%
1か月 パフォーマンス:
-9.34%
6か月 パフォーマンス:
-7.40%
1年 パフォーマンス:
+2.79%
1日の値動き範囲:
$7.07
$7.44
1週間の範囲:
$7.0602
$8.14
52週間の値動き範囲:
$6.70
$18.33
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
名前
Iovance Biotherapeutics Inc
セクター
電話
(650) 260-7120
住所
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
7.38 | 2.25B | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-07-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-09-18 | 繰り返されました | Barclays | Overweight |
| 2023-05-30 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-27 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-08-18 | 再開されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Stifel | Hold → Buy |
| 2021-12-07 | 再開されました | Cowen | Outperform |
| 2021-06-10 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | ダウングレード | Stifel | Buy → Hold |
| 2021-05-03 | 開始されました | Truist | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2021-03-08 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 開始されました | Mizuho | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-04-29 | 開始されました | Piper Jaffray | Overweight |
| 2019-02-28 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-07 | 開始されました | Robert W. Baird | Outperform |
| 2018-12-31 | 再開されました | B. Riley FBR | Buy |
| 2018-07-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-04-10 | アップグレード | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 繰り返されました | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-01 | 繰り返されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Iovance Biotherapeutics Inc (IOVA) 最新ニュース
Barclays PLC Raises Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Where are the Opportunities in (IOVA) - Stock Traders Daily
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Insiders' US$48.3m Investments In Red Following Iovance Biotherapeutics' US$402m Dip In Market Value - Simply Wall St
KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment - Knowledge Ecology International
Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Significant Increase in Short Interest - MarketBeat
State Street Corp Grows Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics' SWOT analysis: promising TIL therapy stock faces growth hurdles - Investing.com India
Interesting IOVA Call Options For January 2025 - Nasdaq
Prediction: This Stock Will Beat the Market in 2025 - Yahoo Finance
BNP Paribas Financial Markets Trims Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics: Steady Progress (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Charles Schwab Investment Management Inc. Has $17.96 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates - MSN
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63% - Yahoo Finance
Braidwell LP Has $2.05 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
(IOVA) On The My Stocks Page - Stock Traders Daily
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect - MSN
Intech Investment Management LLC Makes New $920,000 Investment in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
IOVAIovance Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Is Iovance Biotherapeutics Stock a Millionaire Maker? - MSN
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - GlobeNewswire
Iovance Biotherapeutics (STU:2LB) Operating Cash Flow per S - GuruFocus.com
Iovance Biotherapeutics (NASDAQ:IOVA) delivers shareholders favorable 68% return over 1 year, surging 10.0% in the last week alone - Simply Wall St
IOVA (Iovance Biotherapeutics) Total Assets : $991.12 Mil (As of Sep. 2024) - GuruFocus.com
Victory Capital Management Inc. Buys 115,387 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
IOVA (Iovance Biotherapeutics) Cash Flow from Financing : $389.32 Mil (TTM As of Sep. 2024) - GuruFocus.com
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back - MSN
Landscape Capital Management L.L.C. Takes $615,000 Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Eagle Asset Management Inc. Lowers Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
2 Innovative Stocks That Could Deliver Outsize Returns - Yahoo Finance
Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Iovance Biotherapeutics (STU:2LB) Shares Outstanding (EOP) : 304.62 Mil (As of Sep. 2024) - GuruFocus.com
Long Term Trading Analysis for (IOVA) - Stock Traders Daily
Perceptive Advisors LLC's Strategic Acquisition in Iovance Bioth - GuruFocus.com
Iovance Biotherapeutics director Maynard sells $503k in stock - Investing.com
IOVA (Iovance Biotherapeutics) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Principal Financial Group Inc. - MarketBeat
Iovance Biotherapeutics Q3: A Beat, But A SelloffNow A Buy Opportunity - Seeking Alpha
HC Wainwright Has Positive Outlook for IOVA FY2027 Earnings - MarketBeat
Iovance Biotherapeutics Inc (IOVA) 財務データ
収益
当期純利益
現金流量
EPS
Iovance Biotherapeutics Inc (IOVA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Vogt Frederick G | Interim CEO & General Counsel |
Dec 02 '24 |
Option Exercise |
0.00 |
10,417 |
0 |
214,662 |
| BILINSKY IGOR | Chief Operating Officer |
Dec 02 '24 |
Option Exercise |
0.00 |
3,516 |
0 |
59,323 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Dec 02 '24 |
Option Exercise |
0.00 |
3,906 |
0 |
64,633 |
| Maynard Ryan D | Director |
Nov 12 '24 |
Option Exercise |
7.45 |
50,000 |
372,500 |
57,500 |
| Maynard Ryan D | Director |
Nov 12 '24 |
Sale |
10.06 |
50,000 |
503,000 |
7,500 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):